Search bioRxiv⌕ Search

Biology subjects

Horbinski, C.

Publications and source records attributed to Horbinski, C..

2 recordsLinked to original sources
bioRxiv2019

Integrin α6β4 is downregulated in mutant IDH1 oligodendrogliomas, promotes glioma growth, and associates with a worse outcome in glioma patients

The integrin 6{beta}4 is a laminin receptor that associates with aggressive behavior in many cancers, though its significance in gliomas has not been established. Mutations in isocitrate dehydrogenase 1 and 2 (IDHmut) are common in gliomas, especially 1p/19q co-deleted oligodendrogliomas, and correlate with improved patient survival. We sought to determine whether there is a link between integrin {beta}4 and malignant behavior in gliomas. An inverse relationship was identified between IDHmut and integrin {beta}4 expression in a glioma TMA (P < 0.0001) and in TCGA grade II-IV gliomas (P < 0.0001). Methylation of CpG sites in the ITGB4 promoter is significantly higher in IDHmut gliomas when compared to wild-type tumors, and both ITGB4 methylation and reduced ITGB4 mRNA are not only most prominent in the 1p/19q co-deleted subset of IDHmut tumors, but fully account for the lower ITGB4 expression observed in IDHmut gliomas. In fact, ITGB4 is one of the most downregulated genes in IDHmut 1p/19q co-deleted gliomas compared to IDHmut 1p/19q intact gliomas (P = 3.2x10-39). In patient-derived glioma cells, we found that integrin {beta}4 is enriched in the stem-like population, and that knockdown of integrin {beta}4 slows glioma growth in vitro (P < 0.001) and in vivo (P = 0.01). Lower ITGB4 mRNA levels were also associated with longer overall survival in multiple patient cohorts (P = 0.0005; P < 0.0001). These data suggest that integrin {beta}4 increases glioma malignancy, and that its relative paucity may contribute to the better prognosis in IDH1/2 mutant, 1p/19q co-deleted oligodendrogliomas.

cancer biology↗
bioRxiv2019

CD8+ T-cell-mediated immunoediting influences genomic evolution and immune evasion in murine gliomas

Cancer immunoediting shapes tumor progression by the selection of tumor cell variants that can evade immune recognition. Given the immune evasion and intra-tumor heterogeneity intrinsic to gliomas, we hypothesized that CD8+ T-cells mediate immunoediting in these tumors. We evaluated glioma progression in the absence of CD8+ T-cells by depleting this immune cell population in transgenic murine gliomas. Upon transplantation, gliomas that developed in the absence of CD8+ T-cells engrafted poorly in recipients with intact immunity but engrafted well in those with CD8+ T-cell depletion. Gliomas developed in absence of CD8+ T-cells exhibited increased chromosomal instability, MAPK signaling, gene fusions, and macrophage/microglial infiltration. MAPK activation correlated with macrophage/microglial recruitment in this model and in the human disease. Our results indicate that CD8+ T-cells mediate immunoediting during gliomagenesis, influencing the genomic stability of glioma and its microenvironment, leading to immune evasion.\n\nSignificanceImmune evasion renders cancer resistant to anti-tumoral immunity. Therapeutic intervention often fails for gliomas because of the plasticity of tumor cell variants that resist immune surveillance. Our results demonstrate a mechanism of immune evasion in gliomas that derives from CD8+ T-cells during the development and progression of this disease.

cancer biology↗